Health Kick Podcast: Prescient Therapeutics’ PTX-100 continues to show encouraging results following FDA Orphan Drug Designation
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
Cell and gene therapy is changing the game when it comes to cancer treatment and...
Prescient Therapeutics is hoping to follow in the footsteps of Neuren Pharmaceuticals after positive results...
Telix Pharma (ASX:TLX) announced the US FDA has approved a supplementary New Drug Application (sNDA) for Illuccix,...
Prescient Therapeutics Limited (ASX:PTX) has shared an encouraging update for the ongoing clinical trial of...
Clinical-stage oncology company Prescient Therapeutics Ltd (ASX:PTX) has fielded more promising results from its PTX-100 T Cell...
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has announced continuing positive results in the PTX-100 phase 1b...
Clinical stage oncology company, Prescient Therapeutics (ASX: PTX), has received an expanded Orphan Drug Designation...
Australia's clinical-stage oncology company Prescient Therapeutics (ASX: PTX) -- developing targeted therapies (PTX-100 and PTX-200)...
Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke tells Proactive the company has been granted additional Orphan Drug Designation...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.